header logo image


Page 81«..1020..80818283..90100..»

Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders

February 18th, 2024 2:41 am

FORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the Company”) (NASDAQ: MOTS), today announced that its special meeting of stockholders held on February 16, 2024 (the “Special Meeting”) was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on January 24, 2024 (the “Proxy Statement”).

Read more:
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders

Read More...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

February 18th, 2024 2:41 am

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on February 15, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 40,450 shares of Iovance’s common stock to sixteen new non-executive employees.

Original post:
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Read More...

Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? – InvestorsObserver

February 18th, 2024 2:37 am

Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week?  InvestorsObserver

Continue reading here:
Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver

Read More...

Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? – InvestorsObserver

February 18th, 2024 2:37 am

Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week?  InvestorsObserver

Read this article:
Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver

Read More...

Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? – InvestorsObserver

February 18th, 2024 2:37 am

Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday?  InvestorsObserver

Excerpt from:
Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver

Read More...

Regenerative medicine | NIST

February 10th, 2024 2:33 am

Regenerative medicine therapy, including cell therapy, gene therapy, and therapeutic tissue engineering, provides unprecedented potential to treat, modify, reverse, or cure previously intractable diseases, such as cancer and organ failures. This class of therapy has completely changed the paradigm and the trajectory for medical treatment. Broad clinical translation and patient access requires advances in manufacturing technologies and measurements to ensure the safety, quality, and consistency of the therapy and to reduce the cost.

NIST is committed to solving the measurement challenges of this fast-moving sector of the bioeconomy by providing underpinning measurement infrastructure and platform technologies, as well as standards to promote manufacturing innovation, improve supply chain resilience, and support characterization and testing to facilitate regulatory approval.

The NIST Regenerative Medicine program is working closely with the U.S. Food and Drug Administration'sCenter for Biologics Evaluation and Research(FDA/CBER) and the Standards Coordinating Body (SCB) as well as the broader industry to develop global manufacturing and measurement standards underpinned by a robust measurement infrastructure needed to advance product development and translation as directed by Sec. 3036 of the 21st Century Cures Act.

The NIST laboratory programs support this growing industry as well as the broader industry ecosystem by:

NIST has developed a suite of standards and tools for characterizing biological systems and components using advanced measurement science strategies that enable the generation of high-quality data. Some recent examples of NISTs work include:

See original here:
Regenerative medicine | NIST

Read More...

Ophthalmologists Near Me in Hollywood, FL | Healthgrades

February 2nd, 2024 2:37 am

Anoptometristis a healthcare provider who specializes in routine and preventive eye and vision care. Optometrists diagnose vision abnormalities and prescribe eyeglasses and contacts. They detect and treat cataracts, glaucoma, and eye infections. Optometrists also screen for conditions that affect the eyes and vision, includinghigh blood pressureand diabetes.

An optometrist typically:

Evaluates a patients medical and vision history

Educates the patient about eye and vision disease prevention and health

Performs a comprehensive eye and vision exam and evaluates blood pressure

Performs and interprets specialized eye tests

Diagnoses and often treats acute and chronic eye diseases and conditions that affect vision, including eye injuries, vision problems, cataracts, and glaucoma

Screens for conditions that increase the risk of eye and vision conditions including diabetes and high blood pressure

Prescribes eye glasses, contacts, and certain medications

Refers patients to an ophthalmologist for serious eye problems and most eye surgeries

Performs laser or glaucoma surgeries in some cases

Provides eye and vision care before and after eye surgery

An optometrist may also be known by the following names:eye doctor, vision care specialist, and Doctor of Optometry (OD).

Read the rest here:
Ophthalmologists Near Me in Hollywood, FL | Healthgrades

Read More...

CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a…

January 25th, 2024 2:42 am

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 -

See the original post here:
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a...

Read More...

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

January 25th, 2024 2:42 am

REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor.

Read the original:
Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Read More...

nmible partners with Velocity Clinical Research to streamline clinical trials patient stipends

January 25th, 2024 2:42 am

•  nmible’s solution expected to save more than 650 working days per year, administering payments

View original post here:
nmible partners with Velocity Clinical Research to streamline clinical trials patient stipends

Read More...

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

January 25th, 2024 2:42 am

COPENHAGEN, Denmark, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs).

Visit link:
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Read More...

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

January 25th, 2024 2:42 am

LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced a statement on January 2024, FDA labeling change notifications for approved CAR-T products:

Read the original:
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Read More...

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

January 25th, 2024 2:42 am

HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has filed a second provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence, polyKRASmut. The nanoparticles are developed by Altamira as AM-401.

See the rest here:
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Read More...

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced…

January 25th, 2024 2:42 am

Subject enrollment is expected in Q1 2024 Subject enrollment is expected in Q1 2024

View original post here:
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced...

Read More...

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine…

January 25th, 2024 2:42 am

-Project NextGen Collaboration will Support Capricor’s StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic-

Original post:
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine...

Read More...

PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing

January 25th, 2024 2:42 am

New ticker symbol goes into effect immediately New ticker symbol goes into effect immediately   

Read more here:
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing

Read More...

OrphAI Therapeutics Announces Appointment of Jay Fine to Board of Directors

January 25th, 2024 2:42 am

Seasoned leader in drug discovery and development Seasoned leader in drug discovery and development

Read more:
OrphAI Therapeutics Announces Appointment of Jay Fine to Board of Directors

Read More...

CORRECTION — Sirona Biochem Corporate Update January 2024

January 25th, 2024 2:42 am

VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), please note that in the 8th paragraph of the letter, the company plans to launch its first product early in the 1st quarter of 2025, not the 1st quarter of 2024 as previously stated. The corrected release follows:

See the article here:
CORRECTION -- Sirona Biochem Corporate Update January 2024

Read More...

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

January 25th, 2024 2:42 am

Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM)

Here is the original post:
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

Read More...

23andMe to Report FY2024 Third Quarter Financial Results

January 25th, 2024 2:42 am

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2024 (FY2024) third quarter after the market closes on Wednesday, February 7, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s financial results and report on business progress.

Visit link:
23andMe to Report FY2024 Third Quarter Financial Results

Read More...

Page 81«..1020..80818283..90100..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick